Drug Profile
TRX 2
Alternative Names: TolerMab Anti-CD8 monoclonal antibody; TRX2 antibody - TolerRxLatest Information Update: 01 Sep 2005
Price :
$50
*
At a glance
- Originator TolerRx
- Class Monoclonal antibodies
- Mechanism of Action CD8 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Leukaemia; Transplant rejection
Most Recent Events
- 01 Sep 2005 Discontinued - Preclinical for Leukaemia in USA (unspecified route)
- 01 Sep 2005 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 26 Aug 2002 Preclinical trials in Leukaemia in USA (unspecified route)